{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:38:53Z","timestamp":1794627533487,"version":"4.9.1"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Gallbladder cancer (GBC) mortality remains high and chemoresistance is increasing. This review consolidates what is known about the mechanisms of chemoresistance to inform and accelerate the development of novel GBC-specific chemotherapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Studies related to GBC-related chemoresistance were systematically screened in PubMed using the advanced search function. Search terms included GBC, chemotherapy, and signaling pathway.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Analysis of existing studies showed that GBC has poor sensitivity to cisplatin, gemcitabine (GEM), and 5-fluorouracil. DNA damage repair-related proteins, including CHK1, V-SCR, and H2AX, are involved in tumor adaptation to drugs. GBC-specific chemoresistance is often accompanied by changes in the apoptosis and autophagy-related molecules, BCL-2, CRT, and GBCDRlnc1. CD44<jats:sup>+<\/jats:sup> and CD133<jats:sup>+<\/jats:sup> GBC cells are less resistant to GEM, indicating that tumor stem cells are also involved in chemoresistance. In addition, glucose metabolism, fat synthesis, and glutathione metabolism can influence the development of drug resistance. Finally, chemosensitizers such as lovastatin, tamoxifen, chloroquine, and verapamil are able improve the therapeutic effect of cisplatin or GEM in GBC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This review summarizes recent experimental and clinical studies of the molecular mechanisms of chemoresistance, including autophagy, DNA damage, tumor stem cells, mitochondrial function, and metabolism, in GBC. Information on potential chemosensitizers is also discussed. The proposed strategies to reverse chemoresistance should inform the clinical use of chemosensitizers and gene-based targeted therapy for this disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000989","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T19:03:09Z","timestamp":1677870189000},"page":"131-141","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies"],"prefix":"10.1097","volume":"46","author":[{"given":"Jinbao","family":"Lai","sequence":"first","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Yang","sequence":"additional","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuying","family":"Lin","sequence":"additional","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Huang","sequence":"additional","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhong","family":"Li","sequence":"additional","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenju","family":"Wang","sequence":"additional","affiliation":[{"name":"Yan\u2019an Affiliated Hospital of Kunming Medical University"},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province"},{"name":"Kunming Key Laboratory of Biotherapy, Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1055-9965.EPI-20-0919","article-title":"The role of gallstones in gallbladder cancer in India: a Mendelian randomization study","volume":"30","author":"Mhatre","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/89.15.1132","article-title":"Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer","volume":"89","author":"Zatonski","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41598-021-83300-2","article-title":"Inflammatory profiles in Chilean Mapuche and non-Mapuche women with gallstones at risk of developing gallbladder cancer","volume":"11","author":"Jackson","year":"2021","journal-title":"Sci Rep"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ijc.21683","article-title":"Gallbladder cancer worldwide: geographical distribution and risk factors","volume":"118","author":"Randi","year":"2006","journal-title":"Int J Cancer"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/cancers14051249","article-title":"Evolving paradigms in the systemic treatment of advanced gallbladder cancer: updates in year 2022","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/jcm11082132","article-title":"Oncologic and long-term outcomes of laparoscopic and open extended cholecystectomy for gallbladder cancer","volume":"11","author":"Lee","year":"2022","journal-title":"J Clin Med"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-020-6610-4","article-title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC\/ECC)\u2014a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)-the AIO\/CALGP\/ACO-GAIN-trial","volume":"20","author":"Goetze","year":"2020","journal-title":"BMC Cancer"},{"key":"R12-20250527","first-page":"281","article-title":"Preneoplastic and neoplastic gallbladder lesions occasionally discovered after elective videocholecystectomy for benign disease. A single centre experience and literature review","volume":"84","author":"Paliogiannis","year":"2013","journal-title":"Ann Ital Chir"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine+cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur J Cancer"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.18632\/aging.202488","article-title":"Calreticulin: a potential diagnostic and therapeutic biomarker in gallbladder cancer","volume":"13","author":"Ye","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"34617","DOI":"10.18632\/oncotarget.8964","article-title":"FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.2147\/CMAR.S323759","article-title":"Long Non-coding RNA myosin light chain kinase antisense 1 plays an oncogenic role in gallbladder carcinoma by promoting chemoresistance and proliferation","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbrc.2019.10.104","article-title":"Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma","volume":"522","author":"Xue","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"20194509","DOI":"10.1042\/BSR20194509","article-title":"Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci Rep"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"83060","DOI":"10.18632\/oncotarget.13067","article-title":"MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12935-019-0948-1","article-title":"MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine","volume":"19","author":"Wensheng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.2147\/OTT.S101310","article-title":"The effects of miR-1207-5p expression in peripheral blood on cisplatin-based chemosensitivity of primary gallbladder carcinoma","volume":"9","author":"Shen","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R25-20250527","first-page":"5193","article-title":"First-line treatment of advanced biliary ducts carcinoma: a randomized phase II study evaluating 5-FU\/LV plus oxaliplatin (Folfox 4) versus 5-FU\/LV (de Gramont Regimen)","volume":"37","author":"Schinzari","year":"2017","journal-title":"Anticancer Res"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"101149","DOI":"10.1016\/j.redox.2019.101149","article-title":"aPKC\u03b9 promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1","volume":"22","author":"Tian","year":"2019","journal-title":"Redox Biol"},{"key":"R27-20250527","first-page":"3305","article-title":"miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M","volume":"15","author":"Yu","year":"2018","journal-title":"Oncol Lett"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3892\/or.2021.7947","article-title":"GLI2 but not GLI1\/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer","volume":"45","author":"Ichimiya","year":"2021","journal-title":"Oncol Rep"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"113745","DOI":"10.1016\/j.bcp.2019.113745","article-title":"UCP2 promotes proliferation and chemoresistance through regulating the NF-\u03baB\/\u03b2-catenin axis and mitochondrial ROS in gallbladder cancer","volume":"172","author":"Yu","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2015.10.161","article-title":"NOX1 mediates chemoresistance via HIF1\u03b1\/MDR1 pathway in gallbladder cancer","volume":"468","author":"Zhan","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"6b","key":"R31-20250527","first-page":"5203","article-title":"Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells","volume":"19","author":"Boudny","year":"1999","journal-title":"Anticancer Res"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.omto.2021.08.016","article-title":"lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC","volume":"23","author":"Zheng","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<731::AID-IJC17>3.0.CO;2-H","article-title":"v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells","volume":"80","author":"Masumoto","year":"1999","journal-title":"Int J Cancer"},{"key":"R34-20250527","first-page":"1869","article-title":"DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage\/repair system","volume":"16","author":"Fang","year":"2018","journal-title":"Oncol Lett"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12032-014-0041-5","article-title":"Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression","volume":"31","author":"Fan","year":"2014","journal-title":"Med Oncol"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"101331","DOI":"10.1016\/j.tranon.2021.101331","article-title":"OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1\/caspase-3 axis","volume":"16","author":"Lin","year":"2022","journal-title":"Transl Oncol"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12943-019-1016-0","article-title":"Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy","volume":"18","author":"Cai","year":"2019","journal-title":"Mol Cancer"},{"key":"R38-20250527","first-page":"12116","article-title":"MiR-1231 enhances docetaxel sensitivity to gallbladder carcinoma cells by downregulating FOXC2","volume":"24","author":"Gong","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R39-20250527","first-page":"9829","article-title":"MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma","volume":"23","author":"Wang","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fmolb.2020.00070","article-title":"XRCC1 is a promising predictive biomarker and facilitates chemo-resistance in gallbladder cancer","volume":"7","author":"Wu","year":"2020","journal-title":"Front Mol Biosci"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"43109","DOI":"10.1038\/srep43109","article-title":"miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer","volume":"7","author":"Yang","year":"2016","journal-title":"Sci Rep"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.7150\/jca.38393","article-title":"Anti-tumor activity of bufalin by inhibiting c-MET mediated MEK\/ERK and PI3K\/AKT signaling pathways in gallbladder cancer","volume":"11","author":"Qian","year":"2020","journal-title":"J Cancer"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13046-021-02186-0","article-title":"Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy","volume":"40","author":"Xu","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3390\/jcm10143108","article-title":"Chemotherapy for biliary tract cancer in 2021","volume":"10","author":"Sasaki","year":"2021","journal-title":"J Clin Med"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/egh.10.45","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"4","author":"Weigt","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R47-20250527","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","article-title":"Gemcitabine resistance in pancreatic ductal adenocarcinoma","volume":"23","author":"Binenbaum","year":"2015","journal-title":"Drug Resist Updat"},{"key":"R48-20250527","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","article-title":"Second-line therapies in advanced biliary tract cancers","volume":"21","author":"Tella","year":"2020","journal-title":"Lancet Oncol"},{"key":"R49-20250527","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"R50-20250527","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/cancers14061388","article-title":"Targeting the DNA damage response pathway as a novel therapeutic strategy in colorectal cancer","volume":"14","author":"Catalano","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R51-20250527","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1080\/15384101.2019.1676581","article-title":"Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response","volume":"18","author":"Zhang","year":"2019","journal-title":"Cell Cycle"},{"key":"R52-20250527","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1007\/s10620-018-5253-7","article-title":"BH3 mimetic ABT-199 enhances the sensitivity of gemcitabine in pancreatic cancer in vitro and in vivo","volume":"63","author":"Zhou","year":"2018","journal-title":"Dig Dis Sci"},{"key":"R53-20250527","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jnatprod.2c00104","article-title":"Thiazolidinedione-based structure modification of celastrol provides thiazolidinedione-conjugated derivatives as potent agents against non-small-cell lung cancer cells through a mitochondria-mediated apoptotic pathway","volume":"85","author":"Fu","year":"2022","journal-title":"J Nat Prod"},{"key":"R54-20250527","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett"},{"key":"R55-20250527","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3892\/etm.2021.10142","article-title":"Autophagy-related signaling pathways are involved in cancer (Review)","volume":"22","author":"Chen","year":"2021","journal-title":"Exp Ther Med"},{"key":"R56-20250527","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev-genet-102808-114910","article-title":"Regulation mechanisms and signaling pathways of autophagy","volume":"43","author":"He","year":"2009","journal-title":"Annu Rev Genet"},{"key":"R57-20250527","first-page":"7111","article-title":"Isolation and identification of tumor-initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133","volume":"14","author":"Yu","year":"2017","journal-title":"Oncol Lett"},{"key":"R58-20250527","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13046-018-0864-6","article-title":"LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt\/\u03b2-catenin pathway and predicts poor survival of glioma patients","volume":"37","author":"Zhang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"R59-20250527","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-011-0772-9","article-title":"Lessons from common markers of tumor-initiating cells in solid cancers","volume":"68","author":"Gires","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"R60-20250527","doi-asserted-by":"crossref","first-page":"2004320","DOI":"10.1002\/advs.202004320","article-title":"Colorectal cancer stem cell states uncovered by simultaneous single-cell analysis of transcriptome and telomeres","volume":"8","author":"Wang","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"R61-20250527","first-page":"181","article-title":"Arsenic oxide targets stem cell marker CD133\/prominin-1 in gallbladder carcinoma","volume":"310","author":"Ai","year":"2011","journal-title":"Cancer Lett"},{"key":"R62-20250527","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1472-6882-14-254","article-title":"Differentiation therapy: sesamin as an effective agent in targeting cancer stem-like side population cells of human gallbladder carcinoma","volume":"14","author":"Kong","year":"2014","journal-title":"BMC Complement Altern Med"},{"key":"R63-20250527","doi-asserted-by":"crossref","first-page":"104686","DOI":"10.1016\/j.phrs.2020.104686","article-title":"A unique CDK4\/6 inhibitor: current and future therapeutic strategies of abemaciclib","volume":"156","author":"Chong","year":"2020","journal-title":"Pharmacol Res"},{"key":"R64-20250527","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/d41586-019-01319-y","article-title":"Manipulating the tumour-suppressor protein Rb in lung cancer reveals possible drug targets","volume":"569","author":"Rubin","year":"2019","journal-title":"Nature"},{"key":"R65-20250527","first-page":"11","article-title":"Targeting FAT1 inhibits carcinogenesis, induces oxidative stress and enhances cisplatin sensitivity through deregulation of LRP5\/WNT2\/GSS signaling axis in oral squamous cell carcinoma","author":"Hsu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R66-20250527","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2016-07-726216","article-title":"FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia","volume":"129","author":"Ishizawa","year":"2017","journal-title":"Blood"},{"key":"R67-20250527","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","article-title":"Role of epithelial to mesenchymal transition in hepatocellular carcinoma","volume":"65","author":"Giannelli","year":"2016","journal-title":"J Hepatol"},{"key":"R69-20250527","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial metabolism as a target for cancer therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab"},{"key":"R70-20250527","doi-asserted-by":"crossref","first-page":"115029","DOI":"10.1016\/j.bcp.2022.115029","article-title":"2-Deoxy-D-glucose increases the sensitivity of glioblastoma cells to BCNU through the regulation of glycolysis, ROS and ERS pathways: In vitro and in vivo validation","volume":"199","author":"Sun","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"R71-20250527","first-page":"135438","article-title":"MCL1 participates in leptin-promoted mitochondrial fusion and contributes to drug resistance in gallbladder cancer","volume":"6","author":"Wang","year":"2021","journal-title":"JCI Insight"},{"key":"R72-20250527","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/jcmm.14851","article-title":"Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer","volume":"24","author":"Huang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"R73-20250527","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.bcp.2009.12.006","article-title":"Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation","volume":"79","author":"Wang","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"R74-20250527","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-019-13420-x","article-title":"Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer","volume":"10","author":"Xu","year":"2019","journal-title":"Nat Commun"},{"key":"R75-20250527","doi-asserted-by":"crossref","first-page":"e2770","DOI":"10.1038\/cddis.2017.178","article-title":"miR-218-5p restores sensitivity to gemcitabine through PRKCE\/MDR1 axis in gallbladder cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis"},{"key":"R76-20250527","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.surg.2010.12.010","article-title":"Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells","volume":"150","author":"Zhou","year":"2011","journal-title":"Surgery"},{"key":"R77-20250527","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3892\/or.2015.3755","article-title":"Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-\u03baB-mediated survival signaling pathways in human gallbladder cancer cells","volume":"33","author":"Yu","year":"2015","journal-title":"Oncol Rep"},{"key":"R78-20250527","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Pignochino","year":"2010","journal-title":"BMC Cancer"},{"key":"R79-20250527","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4149\/neo_2012_032","article-title":"Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K\/Akt\/NF-\u03baB signaling pathway in a human breast cancer cell line","volume":"59","author":"Lin","year":"2012","journal-title":"Neoplasma"},{"key":"R80-20250527","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/cancers12040778","article-title":"Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer","volume":"12","author":"Garc\u00eda","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R81-20250527","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ctrv.2015.01.003","article-title":"Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy","volume":"41","author":"Bizama","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R82-20250527","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-020-04100-5","article-title":"Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer","volume":"86","author":"Wang","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"R83-20250527","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.7150\/jca.50292","article-title":"Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT","volume":"12","author":"Ye","year":"2021","journal-title":"J Cancer"},{"key":"R84-20250527","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jcmm.14785","article-title":"\u03b1-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK\/SREBP1 cascades","volume":"24","author":"Shi","year":"2020","journal-title":"J Cell Mol Med"},{"key":"R85-20250527","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.yexcr.2014.11.021","article-title":"Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1\u03b1","volume":"332","author":"Gao","year":"2015","journal-title":"Exp Cell Res"},{"key":"R86-20250527","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/aps.2012.162","article-title":"Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-\u03baB","volume":"34","author":"Zhang","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"R87-20250527","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10616-017-0160-x","article-title":"Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K\/AKT\/ERK pathway","volume":"70","author":"Bi","year":"2018","journal-title":"Cytotechnology"},{"key":"R88-20250527","first-page":"1699","article-title":"Inhibition of mTOR suppresses human gallbladder carcinoma cell proliferation and enhances the cytotoxicity of 5-fluorouracil by downregulating MDR1 expression","volume":"20","author":"Li","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R89-20250527","doi-asserted-by":"crossref","first-page":"12778","DOI":"10.3390\/ijms150712778","article-title":"Cordycepin down-regulates multiple drug resistant (MDR)\/HIF-1\u03b1 through regulating AMPK\/mTORC1 signaling in GBC-SD gallbladder cancer cells","volume":"15","author":"Wu","year":"2014","journal-title":"Int J Mol Sci"},{"key":"R90-20250527","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s12013-014-0061-y","article-title":"Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt\/mTOR pathway","volume":"70","author":"Li","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"R92-20250527","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3727\/096504017X14965095236521","article-title":"Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression","volume":"26","author":"Wang","year":"2011","journal-title":"Oncol Rep"},{"key":"R93-20250527","first-page":"381","article-title":"Mechanism research in somatostatin reverting the chemosensitivity of GBC-SD cell line","volume":"46","author":"Qin","year":"2008","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"R94-20250527","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/scd.2011.0709","article-title":"Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma","volume":"22","author":"Li","year":"2013","journal-title":"Stem Cells Dev"},{"key":"R95-20250527","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/CAD.0b013e328364f935","article-title":"Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1\/TS downregulation might be the mechanism","volume":"24","author":"Cai","year":"2013","journal-title":"Anticancer Drugs"},{"key":"R96-20250527","first-page":"612","article-title":"Effects of autophagy on 5-fluorouracil cytotoxicity for gallbladder carcinoma GBC-SD cell","volume":"94","author":"Tang","year":"2014","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R97-20250527","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.biopha.2010.01.010","article-title":"The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation","volume":"64","author":"Quan","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"R98-20250527","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-010-1481-z","article-title":"Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer","volume":"68","author":"Ocean","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R99-20250527","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1002\/onco.13598","article-title":"A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)","volume":"26","author":"McNamara","year":"2021","journal-title":"Oncologist"},{"key":"R100-20250527","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cncr.33364","article-title":"Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers","volume":"127","author":"Tan","year":"2021","journal-title":"Cancer"},{"key":"R101-20250527","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.critrevonc.2020.102975","article-title":"Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials","volume":"151","author":"Belkouz","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"R102-20250527","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.3390\/cancers13225671","article-title":"Molecular targets and emerging therapies for advanced gallbladder cancer","volume":"13","author":"Canale","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T20:02:36Z","timestamp":1748376156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000989","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}